194471-87-9 Usage
Uses
Used in Peptide Synthesis:
FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID is used as a protecting group for the amino group in the synthesis of peptides. The FMOC group allows for selective deprotection, enabling the controlled coupling of amino acids to form peptide chains. This selective protection is vital for the successful synthesis of complex peptides with specific sequences.
Used in Pharmaceutical Development:
In the pharmaceutical industry, FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID is utilized in the development of drug candidates. Its role in peptide synthesis aids in the creation of novel therapeutic agents, particularly those that involve peptide-based drugs. FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID's ability to protect and deprotect amino groups is essential for the synthesis of bioactive peptides with potential medicinal applications.
Used in Academic Research:
FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID is also employed in academic research settings, particularly in the field of peptide chemistry. Researchers use FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID to explore the properties and reactions of amino acids, as well as to develop new methods for peptide synthesis. Its presence in the lab allows for the investigation of peptide structure, function, and potential applications in various biological contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 194471-87-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,4,4,7 and 1 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 194471-87:
(8*1)+(7*9)+(6*4)+(5*4)+(4*7)+(3*1)+(2*8)+(1*7)=169
169 % 10 = 9
So 194471-87-9 is a valid CAS Registry Number.
InChI:InChI=1/C24H20ClNO4/c25-16-11-9-15(10-12-16)22(13-23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)
194471-87-9Relevant academic research and scientific papers
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
